Steep Rise in U.S. Drug Prices Tied to Patent Monopolies

This article originally appeared here.
Share this content:
Steep Rise in U.S. Drug Prices Tied to Patent Monopolies
Steep Rise in U.S. Drug Prices Tied to Patent Monopolies

WEDNESDAY, Aug. 24, 2016 (HealthDay News) -- Prescription drug prices are skyrocketing in the United States due in large part to government regulations, according to a study published in the Aug. 23/30 issue of the Journal of the American Medical Association.

The current government regulations allow drug manufacturers to charge monopolistic prices that aren't opposed by competing market forces, the researchers believe. Between 2013 and 2015, net spending on prescription drug prices increased about 20 percent in the United States, outpacing a forecast 11 percent increase on all health care costs combined, the authors said in background notes.

For each person in the United States in 2013, $858 was spent on prescription drugs, compared with an average of $400 per person across 19 other industrialized nations. Prescription medications now comprise an estimated 17 percent of overall health care expenses, the authors of the report said.

"The most realistic short-term strategies to address high prices include enforcing more stringent requirements for the award and extension of exclusivity rights; enhancing competition by ensuring timely generic drug availability; providing greater opportunities for meaningful price negotiation by governmental payers; generating more evidence about comparative cost-effectiveness of therapeutic alternatives; and more effectively educating patients, prescribers, payers, and policy makers about these choices," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »